This is a working overview of lipolysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-20. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Derivatives === Derivatives of isoergine include isolysergic acid diethylamide (iso-LSD), isolysergic acid hydroxyethylamide (iso-LSH), and ergometrinine (isoergometrine; isolysergic acid propanolamide), among others. With the apparent exception of isoergine, isolysergamides, such as iso-LSD, have been found to be inactive as psychedelics in humans.
Abdominal obesity, also known as central obesity and truncal obesity, is the human condition of an excessive concentration of visceral fat around the stomach and abdomen to such an extent that it is likely to harm its bearer's health. Abdominal obesity has been strongly linked to cardiovascular disease, Alzheimer's disease, and other metabolic and vascular diseases. Visceral fat, central abdominal fat, and waist circumference show a strong association with type 2 diabetes. Visceral fat, also known as organ fat or intra-abdominal fat, is located inside the peritoneal cavity, packed in between internal organs and torso, as opposed to subcutaneous fat, which is found underneath the skin, and intramuscular fat, which is found interspersed in skeletal muscle. Visceral fat is composed of several adipose depots including mesenteric, epididymal white adipose tissue (EWAT), and perirenal fat. An excess of adipose visceral fat is known as central obesity, the "pot belly" or "beer belly" effect, in which the abdomen protrudes excessively. This body type is also known as "apple shaped", as opposed to "pear shaped" in which fat is deposited on the hips and buttocks. Researchers first started to focus on abdominal obesity in the 1980s when they realized it had an important connection to cardiovascular disease, diabetes, and dyslipidemia. Abdominal obesity was more closely related to metabolic dysfunctions connected with cardiovascular disease than was general obesity.
The simplest kind found in the electron transfer chain consists of two iron atoms joined by two atoms of inorganic sulfur; these are called [2Fe–2S] clusters. The second kind, called [4Fe–4S], contains a cube of four iron atoms and four sulfur atoms. Each iron atom in these clusters is coordinated by an additional amino acid, usually by the sulfur atom of cysteine. Metal ion cofactors undergo redox reactions without binding or releasing protons, so in the electron transport chain they serve solely to transport electrons through proteins. Electrons move quite long distances through proteins by hopping along chains of these cofactors. This occurs by quantum tunnelling, which is rapid over distances of less than 1.4×10−9 m.
=== February === 3 February – A bus veers off a road and overturns in São José da Tapera, Alagoas, killing 16 people. 6–22 February – Brazil at the 2026 Winter Olympics 14 February – Ski racer Lucas Pinheiro Braathen becomes the first athlete representing Brazil and a South American country to win a medal in the Winter Olympics after achieving gold in the men’s giant slalom at the 2026 Winter Olympics in Italy. 16 February – A bus overturns along the BR-153 near Marilia, São Paulo State, killing six people. 21 February – Brazil and India sign an agreement to strengthen cooperation on critical minerals and rare earth elements. 23 February – Brazil announces that it will revoke a decree expanding the waterways in the Amazon rainforest under a federal privatization program following protests by Indigenous groups. 23 February – At least 64 people are killed while five others are reported missing following flash flooding in Juiz de Fora and Ubá, Minas Gerais. 25 February – The Supreme Federal Court convicts five people, including police chief Rivaldo Barbosa and politicians Chiquinho Brazão and his brother Domingos Brazão, for the 2018 assassination of Rio de Janeiro city councilor Marielle Franco and her driver and sentences them to up to 76 years' imprisonment.
=== Restrictive lung diseases === Some types of chronic lung diseases are classified as restrictive lung disease, because of a restriction in the amount of lung tissue involved in respiration. These include pulmonary fibrosis which can occur when the lung is inflamed for a long period of time. Fibrosis in the lung replaces functioning lung tissue with fibrous connective tissue. This can be due to a large variety of occupational lung diseases such as Coalworker's pneumoconiosis, autoimmune diseases or more rarely to a reaction to medication. Severe respiratory disorders, where spontaneous breathing is not enough to maintain life, may need the use of mechanical ventilation to ensure an adequate supply of air.
Sources: en.wikipedia.org
== Sample preparation == Protein samples can be derived from SDS-PAGE or reversed phase HPLC, and are then subject to some chemical modifications. Disulfide bridges in proteins are reduced and cysteine amino acids are carbamidomethylated chemically or acrylamidated during the gel electrophoresis. Then the proteins are cut into several fragments using proteolytic enzymes such as trypsin, chymotrypsin or Glu-C. A typical sample:protease ratio is 50:1. The proteolysis is typically carried out overnight and the resulting peptides are extracted with acetonitrile and dried under vacuum. The peptides are then dissolved in a small amount of distilled water or further concentrated and purified and are ready for mass spectrometric analysis.
China provided a transcript of a 26 April press conference, indicating that an invitation to FDA investigators had been sent on 23 April but making no mention of banning melamine usage. On 3 May 2007, Chinese authorities detained Mao Lijun, general manager of the Xuzhou Anying Biologic Technology Development, one of the companies accused of exporting contaminated protein, on unspecified charges. On 29 May 2007, in actions not linked directly to the protein export scandal, Zheng Xiaoyu (郑筱萸), the former head of China's State Food and Drug Administration (SFDA), had been convicted of personally approving unproven and unsafe medicines after taking bribes from eight pharmaceutical companies totaling more than 6.49 million RMB (approximately 850,000 US dollars). These fraudulent approvals were estimated to have resulted in hundreds of patient deaths; consequently, Zheng was sentenced to death. It was also discovered during his eight years as head of the SFDA, Zheng had personally ordered the approval of more than 150,000 new medicines; by contrast, the U.S. FDA approves approximately 140 new medications per year. Most of those 150,000 medicines were manufactured by the eight pharmaceutical companies that bribed Zheng; one such unsafe medication, produced by the now-defunct Anhui Hua Yuan (华源) Company, resulted in 14 patient deaths and hundreds becoming permanently disabled. Zheng's former deputy was also convicted as an accomplice and given a two-year delayed death sentence.
== Diode Array UV-VIS Detectors == In recent years, diode array UV-Vis detectors have been increasingly used to collect entire spectra at any given moment of data collection. Diode array detectors (DADs) collect entire UV spectra at every point of the eluting peaks while operating as a multi-wavelength UV-Vis detector. This way they give additional information, which help understand more about the nature of the substances appearing in the chromatogram and allow their identification. DADs are the preferred detectors for HPLC method development because they facilitate better peak identification.
Both religions revere John the Baptist, Saint George, and Elijah. Druze, believe that Elijah came back as John the Baptist, or as Saint George, since they belief in reincarnation and the transmigration of the soul, Druze believe that El Khidr and John the Baptist and Saint George are one and the same. Elijah is a central figure of Druzism, and he considered patron of the Druze people. Due to the Christian influence on the Druze faith, two Christian saints become the Druze's favorite venerated figures: Saint George and the Prophet Elijah. Thus, in all the villages inhabited by the Druze and Christians in central Mount Lebanon, a Christian church or Druze maqam is dedicated to either the Prophet Elijah or Saint George. The reverence for Saint George, who is often identified with Al-Khidr, is deeply integrated into various aspects of Druze culture and religious practices. According to scholar Ray Jabre Mouawad, the Druze appreciated the two saints for their bravery, Saint George because he confronted the dragon and the Prophet Elijah because he competed with the pagan priests of Baal and won over them. In both cases the explanations provided by Christians are that Druzes were attracted to warrior saints that resemble their own militarized society. The Druze environment influenced in turn the Christians, and Christians living among Druze started to adopt the same word for some of their churches, using maqām instead of kanīsah (church). Saint George is seen as a guardian of the Druze community and a symbol of their enduring faith and resilience.
== Types == Organisms are broadly grouped into eukaryotes and prokaryotes. Eukaryotic cells possess a membrane-bound nucleus, and prokaryotic cells lack a nucleus but have a nucleoid region. Prokaryotes are single-celled organisms, whereas eukaryotes can be either single-celled or multicellular. Single-celled eukaryotes include microalgae such as diatoms, and some yeasts , species of fungi. Multicellular eukaryotes include all animals, and plants, most fungi, and some species of algae.
Sources: en.wikipedia.org
== External links == GeneReviews/NCBI/NIH/UW entry on Epimerase Deficiency Galactosemia OMIM entries on Epimerase Deficiency Galactosemia UDPgalactose+4-Epimerase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Beyond p53, in cancer, many oncogenes and tumor suppressors have been discovered to be SUMOylated in order for the cancer to progress or not, with each SUMOylation event having one of a variety of effects. When IκB is SUMOylated, the SUMO post-translational modification outcompetes ubiquitination, protecting it from degradation, and by extension, the transcription factor NF-κB is bound in a complex with IκB, preventing the expression of genes that may otherwise cause cells with DNA damage to apoptose. In hypoxic conditions as arise in some cancers, HIF-1α, which is usually SUMOylated followed by subsequent ubiquitination and degradation through the von Hippel-Lindau tumor suppressor's ubiquitin ligase activity, is instead deSUMOylated thereby promoting survival of the tumorigenic cells. The fallout from deSUMOylation of HIF-1α includes promotion of MMPs which are understood to contribute to the progression of EMT, a hallmark of cancer. In atherosclerosis, both p53 and ERK5 are SUMOylated by the stimulus of disturbed blood flow. The stimulus is transduced by the activation of a serine/threonine kinsase called p90RSK, which phosphorylates the human SUMO protease SENP2 at the throenine amino acid residue 368. That phosphorylation is sufficient for the delocalization of the SENP2 from the nucleus. The effects of this phosphorylation-dependent SENP2 inhibition by nuclear export include the SUMOylation of p53 which leads to endothelial cell apoptosis, and SUMOylation of ERK5 which leads to inflammation.
== Nanomaterials in articles, patents, and products == The quantitative analysis of nanomaterials showed that nanoparticles, nanotubes, nanocrystalline materials, nanocomposites, and graphene have been mentioned in 400,000, 181,000, 144,000, 140,000, and 119,000 ISI-indexed articles, respectively, by September 2018. As far as patents are concerned, nanoparticles, nanotubes, nanocomposites, graphene, and nanowires have been played a role in 45,600, 32,100, 12,700, 12,500, and 11,800 patents, respectively. Monitoring approximately 7,000 commercial nano-based products available on global markets revealed that the properties of around 2,330 products have been enabled or enhanced aided by nanoparticles. Liposomes, nanofibers, nanocolloids, and aerogels were also of the most common nanomaterials in consumer products. The European Union Observatory for Nanomaterials (EUON) has produced a database (NanoData) that provides information on specific patents, products, and research publications on nanomaterials.
=== Mi === August Michaelis (1847–1916), German chemist who discovered the Michaelis–Arbuzov reaction Leonor Michaelis (1875–1949), German biochemist and physical chemist known for fundamental advances in enzyme chemistry Hartmut Michel (born 1948), German biochemist, 1988 Nobel Prize in Chemistry for determination of the first crystal structure of an integral membrane protein Huang Minlon (1889–1979), Chinese chemist, pioneer of modern pharmaceutical industries in China Stanley Miller (1930–2007), American chemist, best known for the Miller–Urey experiment Eugène Millon (1812–1867), French military chemist and physician who discovered the reaction of mercury and nitric acid with egg albumen David P. Mills (PhD 2007), British chemist who investigates lanthanide and actinide f-block elements Luis E. Miramontes (1925–2004), Mexican co-inventor of the combined oral contraceptive pill Peter D. Mitchell (1920–1992), British biochemist known for the theory of chemiosmosis, 1978 Nobel Prize in Chemistry Eilhardt Mitscherlich (1794–1863), German chemist, remembered for the law of isomorphism. Alexander Mitscherlich (1836–1918), German chemist known for discovering crystallographic isomorphism
What Is Raynaud's Disease at the National Heart, Lung, and Blood Institute Questions and Answers About Raynaud's Phenomenon at the National Institutes of Health Bakst R, Merola JF, Franks AG, Sanchez M (October 2008). "Raynaud's Phenomenon: Pathogenesis and Management". Journal of the American Academy of Dermatology. 59 (4): 633–53. doi:10.1016/j.jaad.2008.06.004. PMID 18656283.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.